| 5.3 -0.23 (-4.16%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.1 |
1-year : | 9.4 |
| Resists | First : | 6.93 |
Second : | 8.05 |
| Pivot price | 6.78 |
|||
| Supports | First : | 5.14 |
Second : | 4.27 |
| MAs | MA(5) : | 5.8 |
MA(20) : | 6.66 |
| MA(100) : | 5.68  |
MA(250) : | 6.16 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 5.9 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 9.97 | Low : | 2.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FHTX ] has closed above bottom band by 1.3%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.98 - 6.04 | 6.04 - 6.07 |
| Low: | 5.03 - 5.1 | 5.1 - 5.14 |
| Close: | 5.22 - 5.33 | 5.33 - 5.4 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Tue, 16 Apr 2024
Foghorn Therapeutics appoints Kristian Humer as chief financial officer (NASDAQ:FHTX) - Seeking Alpha
Fri, 12 Apr 2024
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth - Simply Wall St
Tue, 09 Apr 2024
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Tue, 09 Apr 2024
Foghorn Therapeutics Unveils Cancer Research Breakthroughs - TipRanks.com - TipRanks
Fri, 05 Apr 2024
Foghorn Therapeutics to Participate in Needham's 23rd - GlobeNewswire
Tue, 02 Apr 2024
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 24.7 (%) |
| Held by Institutions | 61.8 (%) |
| Shares Short | 1,190 (K) |
| Shares Short P.Month | 1,250 (K) |
| EPS | -2.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.84 |
| Profit Margin | -288.2 % |
| Operating Margin | -441.3 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 37.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.8 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -118 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -2.27 |
| PEG Ratio | 0 |
| Price to Book value | -2.9 |
| Price to Sales | 6.6 |
| Price to Cash Flow | -1.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|